title: Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma.
abstract: There is currently no standard first-line regimen for patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTCL). In this study, we investigated the efficacy and toxicity of gemcitabine (GEM) combined with oxaliplatin (L-OHP), L-asparaginase (L-ASP) and dexamethasone (DXM) (GOLD regimen) as a systemic treatment scheme for newly-diagnosed ENKTCL cases. A total of 55 patients were recruited at the Henan Province Cancer Hospital and the Cancer Center of Sun Yat-sen University between May, 2008 and August, 2012. The GOLD regimen included a 14-day treatment cycle with GEM (1,000 mg/m2) on day 1, L-OHP (100 mg/m2) on day 1, L-ASP (10,000 U/m2) on days 1-5 and DXM (20 mg b.i.d.) on days 1-4. The response rate, survival rate and treatment toxicity were analyzed. The overall response rate was 91% (48/55) with a complete response in 62% (34/55) and a partial response in 29% (15/55) of the patients. For all patients, the 1-, 2- and 3-year progression-free survival (PFS) rate was 86, 64 and 57% and the overall survival (OS) 91, 80 and 74%, respectively. The 1-year PFS in patients with stage I/II vs. those with III/IV disease was 87 vs. 66% (P<0.001) and the 1-year OS was 98 vs. 75%, respectively (P<0.001). No chemotherapy-related mortality or severe complications were recorded. In conclusion, the GOLD regimen was found to be highly effective and safe for the treatment of patients with newly-diagnosed ENKTCL.
authors.affiliation: Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China ; Department of Medical Oncology, Henan Province Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
authors.forename: Hong-Qiang
authors.initials: HQ
authors.lastname: Guo
authors.affiliation: Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China ; Department of Medical Oncology, Henan Province Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
authors.forename: Lei
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China ; Department of Medical Oncology, Henan Province Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
authors.forename: Xin-Feng
authors.initials: XF
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, P.R. China.
authors.forename: Tong-Yu
authors.initials: TY
authors.lastname: Lin
authors.affiliation: Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China ; Department of Medical Oncology, Henan Province Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
authors.forename: Shu-Na
authors.initials: SN
authors.lastname: Yao
authors.affiliation: Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China ; Department of Medical Oncology, Henan Province Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
authors.forename: Zhi-Hua
authors.initials: ZH
authors.lastname: Yao
authors.affiliation: Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China ; Department of Medical Oncology, Henan Province Cancer Hospital, Zhengzhou, Henan 450008, P.R. China.
authors.forename: Shu-Jun
authors.initials: SJ
authors.lastname: Yang
keywords: GOLD regimen; chemotherapy; efficacy; extranodal natural killer/T-cell lymphoma; toxicity